GLP 1 study conversations just took a turn from health talk to workplace reality, and the findings are uncomfortable. According to new research from Harvard University economist Rebecca Diamond found that women who started taking GLP 1 weight loss medications saw a notable shift in employment outcomes, especially if they were not working before using the drugs.
According to the National Bureau of Economic Research, Diamond’s working paper is titled “GLP-1–Induced Weight Loss and the Female Obesity Penalty.” The paper was published in June 2026 and has not yet been peer reviewed, which means the findings should be treated as an early look at a serious issue rather than the final word.
Still, the GLP 1 study is already stirring debate because the numbers are hard to ignore. Diamond compared women who started taking GLP 1 drugs with women who wanted to take them but had not started. The employment rate for women who were not working before taking the medications rose 27 percent after about a year and a half.
That finding hits differently because it points to something a lot of women already know too well. People can talk qualifications, work ethic and confidence all day, but appearance still shapes how women are received in rooms where decisions get made. Diamond stated she first became interested in the topic after hearing from people who felt they were treated differently after losing weight on medications like Ozempic or Wegovy.
Diamond put it plainly in the paper.
“Mass pharmacological weight loss is not only a health shock. It is also a shock to the social and labor-market valuation of body weight,” Diamond wrote. “What does not change for women is equally informative.”
According to the University of Southern California’s Understanding America Study, the survey panel Diamond used is a nationally representative, probability based internet panel of about 15,000 United States residents. Diamond used the panel to compare the employment and relationship status of women who began using GLP 1 medications with women who were interested in the drugs but had not yet taken them.
The GLP 1 study did not only look at work. According to Business Insider, women on GLP 1 medications were 29 percentage points more likely to have started living with a partner or gotten married within 18 months. The relationship effect appeared strongest for women who were single before starting the medication.
That is where the conversation gets layered. The study does not prove that every employer or every romantic partner is making choices based on body size. Diamond cautioned against treating the findings as clear causal proof of weight discrimination. But the pattern she identified keeps pointing back to first impressions, the moments when someone is being evaluated by people who do not already know them.
“The arrangements that do not respond are the ones already in place, where any first impression occurred long ago and where weight is one characteristic embedded in a much richer stock of information,” she added.
In other words, women who were already employed did not appear to see major changes in job mobility or income after starting GLP 1 medications. Per Business Insider, women who were already partnered also did not show the same relationship shift. The biggest changes showed up when someone had to make a fresh judgment.
That should make workplaces look in the mirror. According to SHRM, its research found that obese employees were more likely to be perceived as lazy, unmotivated and unprofessional, while average weight employees were more likely to be perceived as high performing, hard working and motivated. That context makes Diamond’s GLP 1 study feel less like a random finding and more like another receipt in a long running conversation about bias.
The popularity of these medications also matters. According to KFF, about one in eight adults said in a 2025 poll that they were currently taking a GLP 1 drug such as Ozempic or Wegovy for weight loss, diabetes or another condition. KFF also reported that nearly one in five adults said they had taken a GLP 1 drug at some point.
The access piece is major too. Diamond’s paper noted that 40 percent of GLP 1 users in the study were paying out of pocket at about $300 a month. Per Business Insider, women who had started the drugs had the highest household incomes, while women who wanted to take them but had not started had the lowest household incomes, suggesting cost may be one barrier.
That raises a bigger question. If weight loss through these medications changes how some women are treated in hiring and dating, what happens to women who cannot afford the same access? The GLP 1 study does not answer every part of that, but it does suggest that medical access, workplace opportunity and social bias may be moving together in ways that deserve more attention.
One of the most surprising parts of the research is what did not change. Diamond said self reported life satisfaction did not show the same kind of improvement, even when employment or relationship status changed.
“Despite life looking better on paper, it doesn’t seem like there’s some subjective wellbeing improvement that is going along with it,” Diamond said.
That line may be the real gut punch. The outside world may start treating someone differently after weight loss, but that does not automatically erase the harm of knowing how conditional that treatment may have been. A job offer, a relationship shift or better social reception can look good on paper, but the emotional math is not always that simple.
For now, the GLP 1 study is less about telling women what to do with their bodies and more about exposing how quickly society can change its tune when a woman’s body changes first. The research is early, but the conversation is not. Women have been clocking beauty politics, body politics and professional double standards for generations, and this paper gives the culture one more reason to stop pretending that appearance does not still carry weight in the rooms that shape people’s lives.
